Business
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)Topline result from preplanned interim futility analysis on track for December 2023HOUSTON, TX / ACCESSWIRE / November 22, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated safety data from the ongoing potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a poster presentation at the SNO 28th Annual Meeting, held November 15-19, 2023 in Vancouver, Canada.Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals presented the poster, which was titled, \"A randomized, controlled trial of Berubicin vs. Lomustine after first-line therapy for glioblastoma multiforme (GBM): Interim Results.\" The poster is now available on the Company's website. The data presented at the SNO Annual Meeting show the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent GBM.\"We continue to be encouraged by the preliminary safety data from Berubicin, and are committed to moving this program forward,\" said Dr. Silberman. \"The preclinical and phase 1 clinical results give us reason to hope that Berubicin will ultimately be shown to provide a much needed clinical benefit for GBM patients, and we remain on track to report the results of our interim analysis of efficacy data in December,\" commented Dr. Silberman.Summary of Updated Safety Results from the Potentially Pivotal Study:Patient demographics are comparable between each arm, including age, gender, race, body surface area (BSA), andKarnofsky Performance Status Scale (KPS). In addition, patients with unmethylated MGMT comprise approximately 40% of each arm, allowing for comparison irrespective of the molecular profile that might influence the efficacy of the therapy administered. Although more patients withdrew from the study in the Lomustine arm than the Berubicin arm, there ...